Skip to main content
Erschienen in: Breast Cancer Research 1/2023

Open Access 01.12.2023 | Retraction Note

Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy

verfasst von: María C. Díaz Flaqué, Natalia M. Galigniana, Wendy Béguelin, Rocío Vicario, Cecilia J. Proietti, Rosalía Cordo Russo, Martín A. Rivas, Mercedes Tkach, Pablo Guzmán, Juan C. Roa, Esteban Maronna, Viviana Pineda, Sergio Muñoz, María Florencia Mercogliano, Eduardo H. Charreau, Patricio Yankilevich, Roxana Schillaci, Patricia V. Elizalde

Erschienen in: Breast Cancer Research | Ausgabe 1/2023

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​bcr3587.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Retraction Note: Breast Cancer Research 2013, 15:R118 https://​doi.​org/​10.​1186/​bcr3587
The Editor-in-Chief has retracted this article. After publication, concerns were raised regarding the western blot images presented in the figures. Specifically:
  • In Fig. 6g, the two pErbB2 blots appear highly similar, including the background features, with a couple of bands showing differences. In the pErbB2 (Tyr927), lanes 6 and 10 appear highly similar, and there appears to be a splice mark to the left of lane 10.
  • In Fig. 6g pp44/pp42 MAPK blot, lanes 3 and 4 appear highly similar to lanes 9 and 10, and there appears to be a splice mark to the left of lane 9.
  • In Fig. 6g p42/p44 MAPK blot, lanes 1 and 5 appear highly similar.
  • In Fig. 8a, there appears to be a splice mark in the p–c-Jun blot between lanes 2 and 3. There are no splices in the c-Jun blot.
  • In Fig. 8f and g, three of the four p42 and p44 MAPK western blot bands appear highly similar, although the figures represent different cells.
The Editor-in-Chief therefore no longer has confidence in the presented data.
María C Díaz Flaqué, Natalia M Galigniana, Patricio Yankilevich and Patricia V Elizalde do not agree to this retraction. None of the other authors have responded to any correspondence from the editor or publisher about this retraction.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Díaz Flaqué MC, Galigniana NM, Béguelin W, et al. Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res. 2013;15:R118. https://doi.org/10.1186/bcr3587.CrossRefPubMedPubMedCentral Díaz Flaqué MC, Galigniana NM, Béguelin W, et al. Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res. 2013;15:R118. https://​doi.​org/​10.​1186/​bcr3587.CrossRefPubMedPubMedCentral
Metadaten
Titel
Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy
verfasst von
María C. Díaz Flaqué
Natalia M. Galigniana
Wendy Béguelin
Rocío Vicario
Cecilia J. Proietti
Rosalía Cordo Russo
Martín A. Rivas
Mercedes Tkach
Pablo Guzmán
Juan C. Roa
Esteban Maronna
Viviana Pineda
Sergio Muñoz
María Florencia Mercogliano
Eduardo H. Charreau
Patricio Yankilevich
Roxana Schillaci
Patricia V. Elizalde
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2023
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-023-01735-z

Weitere Artikel der Ausgabe 1/2023

Breast Cancer Research 1/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.